作者：
Penack, Olaf;Peczynski, Christophe;Boreland, William;Lemaitre, Jessica;Reinhardt, H. Christian;...
通讯作者：
Olaf Penack
作者机构：
Papanicolaou G. Hospital, Thessaloniki, Greece
Department of Hematology and Transplantology, University Clinical Center and Medical University of Gdansk, Gdańsk, Poland
Rigshospitalet, Copenhagen, Denmark
Skåne University Hospital in Lund, Lund, Sweden
EBMT Transplant Complications Working Party, Paris, France
Department of Haematology, University Hospital Centre Rijeka, Rijeka, Croatia
CHU de Saint-Etienne, Hematology, Saint-Etienne, France
University Hospital, Essen, Germany
ASST Papa Giovanni XXIII, Bergamo, Italy
Department of Hematology, Baskent University Hospital, Adana, Türkiye
Department of Hematology, University Hospitals Leuven, Leuven, Belgium
Department of Public Health and Primary Care, ACCENT VV, KU Leuven - University of Leuven, Leuven, Belgium
Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany
Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany
Hematopoietic Stem Cell Unit, Hematology Department, ICMHO, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain
Institut de Cancerologie Lucien Neuwirth, Saint-Étienne, France
RM Gorbacheva Research Institute, Pavlov University, St Petersburg, Russia
Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore-Roma, Roma, Italy
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
Kings’ College Hospital, London, UK
Department of Hematology, Oncology and Internal Medicine, the Medical University of Warsaw, Warsaw, Poland
University Hospital Birmingham NHS Trust, Birmingham, UK
通讯机构：
Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany
EBMT Transplant Complications Working Party, Paris, France
语种：
英文
关键词：
VERSUS-HOST-DISEASE;EXTRACORPOREAL PHOTOPHERESIS
期刊：
Bone Marrow Transplantation
ISSN：
0268-3369
年：
2024
卷：
59
期：
3
页码：
380-386
会议名称：
49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation
会议时间：
APR 23-26, 2023
会议地点：
ELECTR NETWORK
基金类别：
Open Access funding enabled and organized by Projekt DEAL.
摘要：
Ruxolitinib has become the new standard of care for steroid-refractory and steroid-dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between ruxolitinib and extracorporeal photophoresis (ECP). We asked EBMT centers if they were willing to provide detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient. 31 centers responded positively and we included all patients between 1/2017-7/2019 treated with ECP or ruxolitinib for moderate or severe SR-cGVHD. We identified 84 and 57 patients with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-cGVHD...
